Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 6/20 | 0.42 |
| ▸ | MAOA | P21397 | 3/20 | 0.42 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
| ▸ | CES1 | P23141 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3337887 | 0.86 | ALDH1A1 (0.41) | TSHRSMN1; SMN2P2RX7TP53ALDH1A1 | |
| SCHEMBL3337815 | 0.84 | CD38 (0.40) | TSHRALDH1A1 | |
| SCHEMBL15179595 | 0.81 | ABL1 (0.45) | TSHRSMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL7144094 | 0.79 | MAOB (0.44) | MAOBMAOACES2CES1SMN1; SMN2 | |
| SCHEMBL91338 | 0.76 | P2RX7 (0.37) | TSHRSMN1; SMN2P2RX7ALDH1A1ALOX15 | |
| SCHEMBL106184 | 0.76 | MAOB (0.42) | MAOBMAOACES2CES1SMN1; SMN2 | |
| SCHEMBL10290474 | 0.75 | HPGD (0.39) | MAOBMAOAHSD17B1TSHRSMN1; SMN2 | |
| SCHEMBL20326196 | 0.75 | CYP3A4 (0.39) | TSHRSMN1; SMN2MAPTALOX15 | |
| SCHEMBL4120436 | 0.72 | TAAR1 (0.36) | TSHRSMN1; SMN2P2RX7ALDH1A1ALOX15 | |
| Hydrochloric Acid SCHEMBL4220708 | 0.72 | CD38 (0.42) | TSHRP2RX7ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8592452-B2 | Cyclic amine compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-26 | — | — | US | disclosed |
| US-20100152236-A1 | Cyclic amine compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-17 | — | — | US | disclosed |
| US-20100152236-A1 | Cyclic amine compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-17 | — | — | US | disclosed |
| US-20100152236-A1 | Cyclic amine compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-17 | — | — | US | disclosed |
| EP-1911743-A1 | CYCLIC AMINE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2008-04-16 | — | — | EP | disclosed |
| EP-1911743-A1 | CYCLIC AMINE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2008-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152236-A1 | Cyclic amine compound | AR, FSHR, NR5A1 | MAOB 1310/4885MAOA 945/4885HSD17B1 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.